Abstract:Besides their well-established roles in dietary lipid absorption and cholesterol homeostasis, bile acids (BA) also act as metabolically active signaling molecules. The flux of reabsorbed BA undergoing enterohepatic circulation, arriving in the liver with the co-absorbed nutrients (e.g. glucose, lipids), provides a signal that coordinates hepatic triglyceride (TG), glucose and energy homeostasis. As signaling molecules with systemic endocrine functions, BA can activate protein kinases A and C as well as mitogen-activated protein kinase pathways. Additionally, they are ligands for a G-protein-coupled BA receptor (TGR5/Gpbar-1) and activate nuclear receptors such as farnesoid X receptor (FXR; NR1H4). FXR and its downstream targets play a key role in the control of hepatic de novo lipogenesis, very-low-density lipoprotein-TG export and plasma TG turnover. BA-activated FXR and signal transduction pathways are also involved in the regulation of hepatic gluconeogenesis, glycogen synthesis and insulin sensitivity. Via TGR5, BA are able to stimulate glucagon-like peptide-1 secretion in the small intestine and energy expenditure in brown adipose tissue and skeletal muscle. Dysregulation of BA transport and impaired BA receptor signaling may contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Thus, BA transport and BA-controlled nuclear receptors and signaling pathways are promising drug targets for treatment of NAFLD. As such, FXR and/or TGR5 ligands have shown promising results in animal models of NAFLD and clinical pilot studies. Despite being a poor FXR and TGR5 ligand, ursodeoxycholic acid (UDCA) improves hepatic ER stress and insulin sensitivity. Notably, norUDCA, a side chain-shortened homologue of UDCA, improves fatty liver and atherosclerosis in Western diet-fed ApoE(-/-) mice. Collectively, these findings suggest that BA and targeting their receptor/signaling pathways may represent a promising approach to treat NAFLD and closely linked disorders such as obesity, diabetes, dyslipidemia and arteriosclerosis.

Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases

Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver–Gut Axis

Bile acid metabolism and signalling in liver disease

Overview of Bile Acid Signaling in the Cardiovascular System

Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease

Targeting bile acid signaling for the treatment of liver diseases: From bench to bed

Bile acids regulate cardiovascular function

Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases

Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Bile acid-mediated signaling in cholestatic liver diseases

The molecular insights of bile acids homeostasis in host diseases

Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease

New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease

Bile Acid Signaling in the Regulation of Whole Body Metabolic and Immunological Homeostasis.

Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets

Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases

Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols

Bile acids and their effects on diabetes

Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy

Biological Functions and Pharmacological Behaviors of Bile Acids in Metabolic Diseases.

Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism